CRSP News and Press, CRISPR Therapeutics AG From 12/08/23

2023-12-08 11:42:02 ET More on CRISPR Therapeutics, Vertex Pharmaceuticals, etc. CRISPR Gene Editing: Intellia Vs. Crispr Therapeutics Crispr Therapeutics: The Party Is Over (Rating Downgrade) Vertex Pharmaceuticals Looks Expensive, Though It Isn't Biotechs p...

2023-12-08 11:39:48 ET More on bluebird bio bluebird bio Isn't Priced For Success Buy bluebird bio's Lovo-Cel As It Transforms Sickle Cell Disease Treatment bluebird bio, Inc. (BLUE) Q3 2023 Earnings Call Transcript Morgan Stanley ups bluebird to equal weight...

2023-12-08 08:15:00 ET As reported by Fierce Biotech on Nov. 22, gene-therapy star CRISPR Therapeutics (NASDAQ: CRSP) laid off 10% of its employees shortly after reporting its Q3 earnings earlier in the month. Given that the company and its collaborator Vertex Pharmaceuticals ...

2023-12-07 05:30:00 ET In the gene editing therapies space, there aren't any competitors being watched more closely than Vertex Pharmaceuticals (NASDAQ: VRTX) and CRISPR Therapeutics (NASDAQ: CRSP) . The pair scored regulatory approval in the U.K. on Nov. 16 to market their ...

2023-12-06 14:00:00 ET A big week for CRISPR Therapeutics (NASDAQ: CRSP) has gotten even bigger as the biotech company is awaiting a crucial decision. The U.S. Food and Drug Administration (FDA) expects to decide on Friday whether to approve what may become CRISPR Therapeutics' very...

2023-12-05 21:20:00 ET Summary Few areas have been as performance-challenged as biotechnology stocks in the last three years. The S&P Biotechnology Select Industry Index had a return worse than -10% in 2021 and 2022, and recognizing that a lot of 2023 is on the books, 2023 may...

2023-12-05 05:00:00 ET Now is a great time to load up on growth stocks because they may be among the first to benefit in the next bull market. We've already seen some of the biggest ones -- such as Amazon and Apple -- take off as indexes rallied in recent weeks. Buying these longtim...

-Based on preliminary data from ongoing clinical trials, focusing on next-generation CAR T product candidates, CTX112™ targeting CD19 and CTX131™ targeting CD70- -Expanding trials of CTX112 into autoimmune disease, with planned initiation in the first half of 2024, in addi...

2023-12-04 08:30:00 ET The pace of innovation in biotechnology is accelerating at a rapid clip. It took researchers 13 years to sequence the first full human genome. By contrast, it only took CRISPR Therapeutics (NASDAQ: CRSP) 10 years to bring their "molecular scissors" concept to ...

2023-12-04 05:00:00 ET CRISPR Therapeutics ' (NASDAQ: CRSP) stock has soared this year -- and for good reason. The biotech company is getting closer and closer to a major milestone: potential regulatory approval of what may become its first product. In just a few days, the U.S. Food...